Idorsia Ltd
🇨🇭Switzerland
Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03363984
- Locations
- 🇬🇧
Simbec Research Limited, Merthyr Tydfil, Mid Galmorgan, United Kingdom
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03339752
- Locations
- 🇨🇿
Cepha s.r.o., Pilsen, Czechia
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03245229
- Locations
- 🇨🇿
Cepha s.r.o, Plzen, Czechia
A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients
Phase 2
Completed
- Conditions
- Photosensitive Epilepsy
- Interventions
- Drug: ACT-709478 for oral useDrug: Placebo
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03239691
- Locations
- 🇫🇷
HOSP - Bicêtre Neurologie, Le Kremlin-Bicêtre, France
🇩🇪Bethel Epilepsy Center, Mara Hospital, Bielefeld, Germany
🇩🇪Epilepsy Center Frankfurt, Frankfurt, Germany
A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: AC-076 for s.c. administrationDrug: Placebo
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Viatris Innovation GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT03173625
- Locations
- 🇺🇸
Biotrial Inc., Newark, New Jersey, United States
Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT03165097
- Locations
- 🇩🇪
Parexel, Berlin, Germany
A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03165071
- Locations
- 🇨🇿
CEPHA, Plzen, Czechia
A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03101189
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Study to Evaluate ACT-132577 in Healthy Male Subjects
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03100591
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 113
- Registration Number
- NCT03056053
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States
🇺🇸Neurotrials Research Inc, Atlanta, Georgia, United States
🇺🇸Clinical Research CTR of Nevada, Las Vegas, Nevada, United States